Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…Abstract Number: 992 • 2013 ACR/ARHP Annual Meeting
Promise Of Behavioral Economics: Delay Discounting and Physical Activity In Patients With Musculoskeletal Diseases
Background/Purpose: Despite strong evidence that physical activity (PA) is associated with better quality of life, less pain and better functional status in persons with musculoskeletal…Abstract Number: 993 • 2013 ACR/ARHP Annual Meeting
An Analysis Of Healthcare Resource Utilization Among Patients Undergoing Total Knee Arthroplasty In The United Kingdom
Background/Purpose: Elective total knee arthroplasty (eTkA) is among the most commonly performed surgical procedures. The typical reasons for eTkA are pain and decreased quality of…Abstract Number: 996 • 2013 ACR/ARHP Annual Meeting
Predictors and Modeling of Costs in Rheumatoid Arthritis
Background/Purpose: Costs in RA are substantial with 2-3 times higher mean annual costs than in the general population, but with a skewed cost distribution.[1] As…Abstract Number: 1003 • 2013 ACR/ARHP Annual Meeting
Measuring Economic Value of Morning Stiffness; Consistency Over 1 Year
Background/Purpose: Economic evaluation of health care activities requires often measuring clinical symptoms and their changes also in monetary terms. Patients with rheumatoid arthritis (RA) may…Abstract Number: 1004 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis
Background/Purpose: socioeconomic costs of rheumatoid arthritis (RA) are very high. Biologic therapies with different biologic targets are now available for moderate to severe RA, and…Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting
Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study
Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization. Studies on health use and costs are…Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…Abstract Number: 379 • 2013 ACR/ARHP Annual Meeting
Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts
Background/Purpose: The risk of osteoporotic fracture is known to be high in RA. Yet less is known about RA related predictive factors for this…Abstract Number: 60 • 2012 ACR/ARHP Annual Meeting
The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is estimated to be one of the leading causes of non-fatal burden in the world. However, data from developing countries including…Abstract Number: 2646 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia
Background/Purpose: Although fibromyalgia is associated with substantial annual direct medical and indirect productivity costs, the cost-effectiveness of treatments for fibromyalgia remains understudied. A randomized…Abstract Number: 270 • 2012 ACR/ARHP Annual Meeting
Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
TITLE: "Use of drug combinations in patients with osteoarthritis: a population-based cohort study."Background/Purpose: Patients affected with osteoarthritis (OA) use different drugs in search for relief.…Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…
ACR Meeting Abstracts